Merck’s $8B Keytruda Quarter Masks Looming Patent Cliff
Merck’s blockbuster cancer immunotherapy Keytruda just delivered its first $8 billion quarter, but the pharmaceutical giant faces a critical deadline. With patent protection expiring in 2028, the company is racing to cut costs and diversify beyond its flagship product.